Efficacy Of Permanent Brachytherapy Combined With Maximal Androgen Blockade In The Treatment Of Prostate Cancer

Objectives: To evaluate the outcomes and complications in prostate cancer patients who were treated with permanent iodine-125 brachytherapy(BT)combined with maximum androgen blockade(MAB).Methods: The clinical data of 257 prostate cancer cases treated at our institution or east Division of Suzhou Municipal Hospital during Sept.2012 and Sept.2016 were retrospectively analyzed.The selection criteria were the following: follow-up ?6 months;chest X-ray or CT,abdominal cavity CT or MRI and bone scan were conducted to exclude metastatic lesions;primary tumor(T)staging: T2 ~ T3.A total of 109 cases were enrolled for further analysis.Aged from 50 to 89 years.Prostrate volume ranged from 11.73 to122.10 ml.Gleason score 6-10.Serum PSA from 4.16 to 189.10 ng/ml.48 patients undergoing iodine-125 BT combined with MAB as the observation group,and another 61 cases treated with MAB as the control group.There was no statistical difference in the general data of the two groups(P>0.05).The prostate specific antigen(PSA)level,biochemical progress-free survival(b PFS)and complications of the two groups were compared.Results: The PSA level after treatment in the two groups was significantly lower than that before treatment(P<0.001).The PSA level in the observation group was lower than control group after treatment for 9,12,18 and 24 months(P<0.05).The b PFS in the observation group(20.79±10.60 months)was significantly longer than that in the control group(16.10±10.87 months)(P=0.026).Low-urinary tract occurred in 22 cases(45.83%)in the observation group and 17 cases(27.87%)in the control group.There is a statistical difference between the two groups(P=0.041).No serious complications were observed during the follow-up.Conclusion: The permanent iodine-125 brachytherapy combined with maximal androgen blockade are effective and minimal invasive to treat prostate cancer.